Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery

Abstract

BackgroundCardiopulmonary bypass may have detrimental effects on intestinal function and decrease the concentrations of the active, long-acting metabolites of levosimendan, an inodilator used to improve cardiac function. The aim of this study was to evaluate the haemodynamic effects of preoperative levosimendan in patients undergoing high-risk cardiac surgery. MethodsTwenty-four patients were randomized to receive levosimendan (12 µg bolus followed by an infusion of 0.2 µg kg−1 min−1) or a placebo 24 h before surgery. The inclusion criteria were left ventricular ejection fraction (LVEF) <50% or LV hypertrophy indicated by a wall thickness of >12 mm. Haemodynamics were recorded every hour for 24 h (pulmonary artery catheter) and daily until postoperative day 4 (whole-body impedance cardiography). Doppler echocardiography with tissue Doppler imaging was used to assess systolic and diastolic cardiac function. ResultsThe cardiac index (CI) and stroke volume index (SI) were higher in the levosimendan group (LG) for the 4 day postoperative period (P<0.05); on the fourth postoperative day, the CI was 3.0 litre m−2 min−1 in the LG compared with 2.4 litre m−2 min−1 in the control group (CG) and the SI was 30 vs 25 ml m−2, respectively. The LVEF measured at baseline and on the fourth postoperative morning decreased in the CG, but was maintained in the LG. ConclusionsLevosimendan improved haemodynamics compared with a placebo in patients undergoing high-risk cardiac surgery. The concentrations of levosimendan’s metabolites were higher compared with earlier studies using perioperative dosing.URL: https://register.clinicaltrials.govClinicalTrials.gov Identifier: NCT01210976